How to discover the exceptional venetoclax responders in AML/MDS?

Br J Haematol. 2024 Jan;204(1):14-15. doi: 10.1111/bjh.19165. Epub 2023 Nov 2.

Author

Bjørn Tore Gjertsen^{1

2}

Affiliations

¹ Centre for Cancer Biomarkers (CCBIO), Department of Clinical Science, University of Bergen, Bergen, Norway.
² Hematology Section, Department of Medicine, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway.

PMID: 37920123
DOI: 10.1111/bjh.19165

No abstract available

Keywords: DDX41; AML; MDS; exceptional responders; hypomethylating agent; real-world analysis; venetoclax.

Publication types

Comment

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides